Described are compounds of the formula (I) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.
Disclosed are compounds according to Formula I:
wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity.
Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.
Introducing two remote functional groups into rings via chain-walking represents a new strategy to efficiently access multi-substituted saturatedcyclic compounds. We report an unprecedented 1,3-cis-carboboration of cyclohexenes by nickel catalysis. The application of LiOMe as base plays a crucial role in the success of this reaction.